Skip to content

US · AYTU · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Aytu BioPharma, Inc. (AYTU) intrinsic value and stock valuation

$2.66as of 2026-11-21 · Mkt cap 25.33M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aytu BioPharma, Inc. DCF and intrinsic value

InvestorsCraft values AYTU with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AYTU’s statements →

Aytu BioPharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Denver, CO 80237 aytubio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$66.4M+19.2% 5y CAGRd
20112025
Net income
-$-13.56M
20112025
Free cash flow
-$-5.17M
20112025
Total equity
$19M-27.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$66.4M$65.2M$107.4M$96.7M$65.6M
Operating income-$-7.83M-$-1.59M-$-17.07M-$-109.91M-$-58.87M
Net income-$-13.56M-$-15.84M-$-17.05M-$-108.78M-$-58.29M
EPSd-$-2.16M-$-2.86M-$-5.1M-$-74M-$-69.39M
Operating cash flow-$-1.94M-$-1.39M-$-5.13M-$-28.82M-$-25.96M
Capital expenditure-$-3.23M-$-330K$0.00$0.00$0.00
Free cash flow-$-5.17M-$-1.72M-$-5.13M-$-28.82M-$-25.96M
Total assets$124.2M$118.9M$137.8M$137.6M$265.7M
Total debt$22.9M$16.4M$30.4M$18.2M$31M
Net debt-$-8.02M-$-3.59M$7.44M-$-1.17M-$-18.68M
Total equity$19M$27.7M$39.4M$44.3M$137.6M
Cash and short-term investments$31M$20M$23M$19.4M$49.7M
Income statement
20252024202320222021
Revenue$66.4M$65.2M$107.4M$96.7M$65.6M
Cost of revenue$20.6M$16.1M$40.8M$46.4M$36.4M
Gross profit$45.8M$49.1M$66.6M$50.3M$29.2M
Research and development expenses$1.33M$2.77M$4.09M$12.7M$5.62M
Selling, general and administrative expenses$38.3M$42M$70.1M$69.9M$55.8M
Other expenses$14.1M$5.84M$9.52M$77.7M$26.6M
Operating expenses$53.7M$50.7M$83.7M$160.2M$88.1M
Cost and expenses$74.2M$66.8M$124.5M$206.6M$124.5M
Interest income$0.00$0.00$0.00$10K$0.00
Interest expense$3.7M$4.79M$4.96M$147.5M$0.00
Depreciation and amortization$5.38M$6.72M$8.81M$10.2M$9.2M
Ebitda-$-4.67M$1.41M-$-3.27M-$-27.96M-$-29.04M
Operating income-$-7.83M-$-1.59M-$-17.07M-$-109.91M-$-58.87M
Total other income/expenses, net-$-5.92M-$-8.79M$10K$1.02M$840K
Income before tax-$-13.74M-$-10.38M-$-17.05M-$-108.89M-$-58.03M
Income tax expense$440K$2.14M$0.00-$-110K$260K
Net income-$-13.56M-$-15.84M-$-17.05M-$-108.78M-$-58.29M
Weighted average shares outstanding$6.28M$5.54M$3.34M$1.47M$840K
Weighted average diluted shares outstanding$6.28M$5.54M$3.34M$1.47M$840K
Balance sheet
20252024202320222021
Cash and short-term investments$31M$20M$23M$19.4M$49.7M
Net receivables$31.2M$23.5M$28.9M$21.7M$28.2M
Inventory$11.4M$12.1M$12M$10.9M$16.3M
Total current assets$79.2M$61.9M$72.8M$59.9M$105.2M
Property, plant and equipment, net$1.59M$1.52M$3.87M$6.3M$8.7M
Goodwill and intangible assets$42.2M$52.5M$59M$70.6M$151.3M
Long-term investments$0.00$0.00$0.00$0.00-$-10.91M
Total non-current assets$45M$57M$65M$77.7M$160.4M
Total assets$124.2M$118.9M$137.8M$137.6M$265.7M
Accounts payable$10.6M$10.3M$13.5M$11M$19.3M
Short-term debt$11.1M$4.96M$8.74M$3.91M$25.5M
Deferred revenue$0.00$0.00$0.00$0.00$57.2M
Total current liabilities$63.1M$62.2M$69M$64.4M$109.4M
Long-term debt$11.9M$11.5M$21.7M$14.3M$5.43M
Deferred revenue, non-current$0.00$0.00$0.00$0.00-$-11.15M
Total non-current liabilities$42.2M$28.9M$29.5M$28.9M$18.7M
Capital lease obligations$1.12M$1.29M$830K$180K$3.56M
Total liabilities$105.2M$91.1M$98.5M$93.3M$128.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-333.54M-$-319.97M-$-304.13M-$-287.08M-$-178.3M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$0.00$0.00
Total equity$19M$27.7M$39.4M$44.3M$137.6M
Total investments$0.00$0.00$0.00$0.00-$-10.91M
Total debt$22.9M$16.4M$30.4M$18.2M$31M
Net debt-$-8.02M-$-3.59M$7.44M-$-1.17M-$-18.68M
Cash flow statement
20252024202320222021
Net income-$-13.56M-$-15.84M-$-17.05M-$-108.78M-$-58.29M
Depreciation and amortization$5.38M$6.72M$8.81M$10.2M$9.2M
Stock-based compensation$580K$2.37M$6.05M$5.25M$3.57M
Change in working capital-$-5.73M-$-4.66M-$-5.8M-$-10.86M$1.68M
Accounts receivable-$-7.63M$5.2M-$-7.15M$6.53M$1.54M
Inventory$380K-$-4.82M-$-3.61M$1.3M$2.79M
Accounts payable$290K-$-2.08M$2.38M-$-7.68M-$-3.25M
Net cash provided by operating activities-$-1.94M-$-1.39M-$-5.13M-$-28.82M-$-25.96M
Investments in property, plant and equipment-$-230K-$-330K$0.00$0.00$0.00
Acquisitions, net$0.00$0.00-$-10K-$-3.18M-$-480K
Net cash used for investing activities-$-2.56M-$-330K-$-120K-$-3.25M-$-2.78M
Common stock issued$14.8M$3.47M$15.6M$11.7M$40.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.4M-$-1.26M$8.87M$1.53M$30.3M
Net change in cash$11M-$-2.98M$3.62M-$-30.54M$1.57M
Cash at end of period$31M$20M$23M$19.4M$49.9M
Operating cash flow-$-1.94M-$-1.39M-$-5.13M-$-28.82M-$-25.96M
Capital expenditure-$-3.23M-$-330K$0.00$0.00$0.00
Free cash flow-$-5.17M-$-1.72M-$-5.13M-$-28.82M-$-25.96M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aytu BioPharma, Inc.

        Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

        CEO
        Joshua R. Disbrow
        Employees
        83
        Beta
        0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Aytu BioPharma, Inc. (AYTU)?

        Aytu BioPharma, Inc. (AYTU) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AYTU undervalued?

        AYTU trades at a price of $2.66 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.